Skip to main content

NEUROCRINE BIOSCIENCES INC

For the period ended May 22, 2024. Filed Apr 10, 2024.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

May 22, 2024 · Filed Apr 10, 2024

NBIX$164.63+3.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant☒ Filed by a Party other than the Registrant☐

Check the appropriate box:

☐Preliminary Proxy Statement
☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒Definitive Proxy Statement
☐Definitive Additional Materials
☐Soliciting Material Pursuant to §240.14a-12

Neurocrine Biosciences, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒No fee required.
☐Fee paid previously with preliminary materials.
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

NEUROCRINE BIOSCIENCES, INC.

6027 Edgewood Bend Court

San Diego, CA 92130

Notice of Annual Meeting of Stockholders

To Be Held on May 22, 2024

TO THE STOCKHOLDERS:

NOTICE IS HEREBY GIVEN that the 2024 Annual Meeting of Stockholders of Neurocrine Biosciences, Inc., a Delaware corporation (the “Company”), will be held on May 22, 2024, at 10:30 a.m., local time, at the Company’s corporate offices located at 6027 Edgewood Bend Court, San Diego, California 92130, for the following purposes as more fully described in the Proxy Statement accompanying this Notice:

  1. The election of the four nominees for Class I directors named herein to the Board of Directors to serve for a term of three years;

  2. An advisory vote on the compensation paid to the Company’s named executive officers;

  3. To approve an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 3,635,000 shares;

  4. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; and

  5. To transact such other business as may properly come before the Annual Meeting of Stockholders or any continuation, adjournment or postponement thereof.

Only stockholders of record at the close of business on March 25, 2024 are entitled to receive notice of and to vote at the Annual Meeting of Stockholders.

All stockholders are invited to attend the Annual Meeting of Stockholders in person. However, we strongly urge our stockholders not to attend the Annual Meeting in person and to instead submit proxy votes. Our Annual Meeting will be purely functional in format to comply with the relevant legal requirements. There will be no presentations or exhibitions. No refreshments will be provided. Your vote is important. Whether or not you plan to attend the Annual Meeting, we encourage you to submit your proxy or voting instructions as soon as possible to vote your shares. You may vote over the Internet, as well as by telephone or by mailing a proxy or voting instruction form. Please review the instructions on each of your voting options described in these proxy materials. Stockholders attending the Annual Meeting may vote in person even if they have returned a proxy. If you hold shares through an account with a brokerage firm, bank or other nominee, please follow the instructions you receive from such firm, bank or other nominee to vote your shares.

By Order of the Board of Directors,

Darin Lippoldt

Chief Legal Officer and Corporate Secretary

San Diego, California

April 10, 2024

Important Notice Regarding the Availability of Proxy Materials for the Stockholders’

Meeting to be Held on May 22, 2024 at 10:30 a.m. Local Time at

6027 Edgewood Bend Court, San Diego, California 92130.

The Proxy Statement and Annual Report to stockholders are available at

www.proxyvote.com. Please have the control number on your proxy card available.

A copy of the Company’s Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2023 is available without charge upon written request to the Company’s Corporate Secretary at

12780 El Camino Real, San Diego, California 92130.

TABLE OF CONTENTS

Proxy Summary1Our Compensation Practices44
About the Annual Meeting2Role of the Compensation Committee44
Security Ownership of Certain Beneficial Owners and Management5Compensation Philosophy45
Our Board of Directors7Overall Compensation Determination Process45
General7Compensation Consultant46
Director Biographies of Class I Directors Nominated for Reelection at the 2024 Annual Meeting of Stockholders7Competitive Assessment of Compensation—Peer Group and Market Data47
Director Biographies of Class II and Class III Directors not Nominated for Reelection at the 2024 Annual Meeting of Stockholders8Components of Executive Compensation47
The Board of Directors and Corporate Governance Matters102023 Named Executive Officer Compensation Decisions50
General10Officer Equity Ownership Guidelines54
Corporate Governance Best Practices10Equity Trading Policies and Procedures54
Board of Directors Overview11Compensation Recoupment Policy55
Board Leadership Structure12Tax and Accounting Considerations55
Board Independence12Risk Analysis of Our Compensation Program55
Classified Board Structure12Executive Compensation and Other Information56
Overboarding Policy12Summary Compensation Table56
Board and Committee Meetings During 202313Grants of Plan-Based Awards During 202357
Information About Board Committees13Agreements with Named Executive Officers58
Compensation Committee Interlocks and Insider Participation14Outstanding Equity Awards at Fiscal Year-End59
Director Nomination Process14Option Exercises and Stock Vested During the Year60
Board Diversity Matrix15Potential Payments upon Termination or Change-in-Control60
Board Self Assessment15CEO Pay Ratio64
Board Education15Item 402(v) Pay Versus Performance65
Identification and Evaluation of Nominees for Director15Directors Compensation Summary69
Proxy Access16Non-Employee Director Compensation Philosophy69
Process for Stockholder Communications with the Board of Directors16Non-Employee Director Compensation for 202369
The Board's Role in Risk Oversight16Director Compensation Table70
Corporate Responsibility and Sustainability17Non-Employee Director Compensation for 202470
Risk Assessment Concerning Compensation Practices and Policies17Non-Employee Director Equity Ownership Guidelines71
Role of Board in Succession Planning18Additional Information71
Policy Regarding Board Member Attendance at the Company's Annual Meeting18Related Person Transactions71
Report of the Audit Committee19Other Matters71
Principal Accountant Fees and Services20Additional Information71
Compensation Committee Report21Special Note Regarding Forward-Looking Statements72
Proposal One: Election of Directors22Appendix A - 2020 Equity Incentive Plan73
Proposal Two: Advisory Vote on Compensation Paid to the Company's Named Executive Officers24
Proposal Three: Approval of an Amendment to the 2020 Equity Incentive Plan25
Equity Compensation Plans37
Proposal Four: Ratification of Appointment of Independent Registered Public Accounting Firm38
Executive Officers39
Compensation Discussion and Analysis41
Executive Summary41
Committee Actions in Connection with Say-on-Pay Vote42
Pay for Performance / At-Risk Pay43
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.